The total number of records retrieved from this search are 15. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1907	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_1908	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_1909	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_1910	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_1911	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_1912	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result25% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_1913	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result5% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_1914	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_1915	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMalignan small cell canine carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for MTH52c cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultSignificant decrease in tumor volume after 42 days	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus cause increase expression of ApoA1, IL-2,11,18,IFN-gamma, IP-10, MCP-1,3,5,MIP-2,MMP-9 and TNF alpha	Clinical trialNA	PMID20631910
IDOV_4084	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4088	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4092	Virus nameVaccinia virus	Virus strainVVstrain LIVP 6.1.1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationMutant for J2R gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result25% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4096	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result95% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4100	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404
IDOV_4104	Virus nameVaccinia virus	Virus strainVVstrain GLV-5b451	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDerived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of veterinary medicine, germany	Origin of cell lineHuman mammary carcinoma cell line	Cell lineMTH52c	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26205404